DRUG
HEALTHCAREBright Minds Biosciences Inc
Live · NASDAQ · May 9, Close
What's Moving DRUG Today?
No stock-specific AI insight has been generated for DRUG yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$88.90
Fundamentals
Trading
DRUG News
20 articles- What Is the Probability of Success for Bright Minds Biosciences Inc (DRUG)’s Lead Drug Candidate?Yahoo Finance·Mar 25, 2026
- Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study resultsYahoo Finance·Mar 6, 2026
- Bright Minds Biosciences to Present at Upcoming ConferencesYahoo Finance·Feb 25, 2026
- Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming TrialsYahoo Finance·Feb 19, 2026
- Canadian Securities Exchange Reports January 2026 Performance FiguresYahoo Finance·Feb 17, 2026
- Bright Minds Biosciences Announces Closing of US$175 Million Public OfferingYahoo Finance·Jan 9, 2026
- Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common StockYahoo Finance·Jan 8, 2026
- Bright Minds Biosciences Announces Launch of US$100 Million Public OfferingYahoo Finance·Jan 6, 2026
- Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)Yahoo Finance·Jan 6, 2026
- Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026Yahoo Finance·Jan 5, 2026
- Recent Price Trend in Bright Minds Biosciences Inc. (DRUG) is Your Friend, Here's WhyYahoo Finance·Nov 26, 2025
- Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual MeetingYahoo Finance·Nov 25, 2025
- Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a BetYahoo Finance·Nov 25, 2025
- Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)Yahoo Finance·Nov 17, 2025
- Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6THYahoo Finance·Nov 6, 2025
- Bright Minds Biosciences Inc. (DRUG) is on the Move, Here's Why the Trend Could be SustainableYahoo Finance·Oct 15, 2025
- Wall Street Analysts Believe Bright Minds Biosciences Inc. (DRUG) Could Rally 81.29%: Here's is How to TradeYahoo Finance·Sep 18, 2025
- Large Patient Population Is Key Driver For Bright Minds' GrowthYahoo Finance·Sep 8, 2025
- Weekly Roundup on the Cannabis Sector & Psychedelic SectorYahoo Finance·Sep 7, 2025
- Bright Minds Biosciences Announced OfferingYahoo Finance·Sep 5, 2025
All 20 articles loaded
Price Data
52-Week Range
$88.90
Fundamentals
Trading
About Bright Minds Biosciences Inc
Bright Minds Biosciences Inc. (DRUG) is a pioneering clinical-stage biotechnology firm dedicated to developing cutting-edge therapies aimed at addressing central nervous system disorders, particularly in mental health and pain management. Leveraging its proprietary drug development platform, the company is advancing a robust pipeline of candidates that prioritize both efficacy and safety, amidst the increasing acceptance of psychedelic treatments. With a seasoned management team and a strong intellectual property portfolio, Bright Minds is strategically positioned to capture the growing demand for innovative mental health solutions, making it an attractive prospect for institutional investors seeking exposure to the evolving pharmaceutical landscape.